The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Dynavax Technologies Corporation (DVAX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.36, or -3.47%, to $10.01. Volume reached 121,366 shares, with price reaching a high of $10.07 and a low of $9.6. Earlier, Yahoo Finance discussed this stock as it revealed Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $10.07 and fluctuated between $10.49 as its day high and $10.07 as its day low. The current market capitalization of Dynavax Technologies Corporation is $1.29B. A total of 1.76 million shares were traded on the day, compared to an average of 2.05M shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, DVAX has seen 8 BUY and 9 SELL insider trades, representing the acquisition of 113,685 and the disposition of 3,108,131 shares. Over the last 12 months, there were 26 BUYs and 26 SELLs from insiders. Insiders purchased 483,479 shares during that period but sold 3,414,032.
In the most recent transaction, Hack Andrew A. F. sold 3,000,000 shares of DVAX for 14.68 per share on Aug 15. After the transaction, the Director now owns 5,415,000 company shares. In a previous transaction on Aug 09, Janssen Robert sold 7,938 shares at 16.92 per share. DVAX shares that Senior Vice President owns now total 35,519.
Among the insiders who sold shares, Novack David F disposed of 26,250 shares on Aug 09 at a per-share price of $16.92. This resulted in the President & COO holding 53,213 shares of DVAX after the transaction. In another insider transaction, Spencer Ryan sold 14,921 shares at $16.92 per share on Aug 09. Company shares held by the CEO and Director now total 144,513.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for DVAX in the last 3 months, the mean price target is $25.50 with high estimates of $30.00 and low estimates of $20.00. In terms of 52-week highs and lows, DVAX has a high of $21.39 and a low of $7.26.
As of this writing, DVAX has an earnings estimate of $0.33 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of $0.42 per share and a lower estimate of $0.23. The company reported an EPS of $0.86 in the last quarter, which was 290.91% higher than expectations of $0.22.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. DVAX’s latest balance sheet shows that the firm has $545.95M in Cash & Short Term Investments as of fiscal 2021. There were $257.38M in debt and $556.40M in liabilities at the time. Its Book Value Per Share was $3.35, while its Total Shareholder’s Equity was $222.37M.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 5 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DVAX is Overweight with a score of 5.00. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.